Bicara Therapeutics leases new Boston HQ space

Bicara Therapeutics Inc. (BCAX) entered into a Sub-Sublease Agreement with Wayfair LLC to lease approximately 35,090 square feet of office space for its new corporate headquarters at 10 St.

Rhea-AI Filing Summary

Bicara Therapeutics Inc. (BCAX) entered into a Sub-Sublease Agreement with Wayfair LLC to lease approximately 35,090 square feet of office space for its new corporate headquarters at 10 St. James Avenue, Boston, Massachusetts 02116. The sublease term will commence on the later of October 1, 2026 or the date a required multi-party consent is fully executed, defined as the Commencement Date. The base rent is $105,279 per month, beginning nine months after the Commencement Date, and Bicara paid a $210,540 security deposit at signing. The sublease will end on the earlier of September 30, 2028 or an earlier termination under its terms and includes customary events of default, representations, warranties and covenants.

8-K Event Classification

2 items: 1.01, 9.01

2 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Headquarters space leased: 35,090 square feet Monthly base rent: $105,279 per month Security deposit: $210,540 +2 more

5 metrics

Headquarters space leased 35,090 square feet Office space at 10 St. James Avenue, Boston, Massachusetts 02116

Monthly base rent $105,279 per month Base rent under the Sub-Sublease, payable nine months after Commencement Date

Security deposit $210,540 Security deposit paid upon entry into the Sub-Sublease Agreement

Sublease start reference date October 1, 2026 Sublease term commences on the later of this date or consent execution

Sublease end date September 30, 2028 Sublease term ends on this date or earlier if terminated under its terms

Key Terms

Sub-Sublease Agreement, Commencement Date, security deposit, events of default

4 terms

Sub-Sublease Agreement financial

"entered into a Sub-Sublease Agreement (the “Sublease”) with Wayfair LLC"

Commencement Date financial

"the “Commencement Date”"

security deposit financial

"The Company paid a security deposit totaling $210,540"

events of default financial

"The Sublease contains customary events of default, representations, warranties"

Events of default are specific breaches or failures listed in a loan, bond, or credit agreement that give lenders the right to act, such as demanding immediate repayment, raising interest rates, or taking secured assets. They matter to investors because triggering one is like setting off a financial alarm: it raises the chance of foreclosure, restructuring, or bankruptcy and can sharply reduce the value of a company’s stock or bonds and increase borrowing costs.

FAQ

What agreement did Bicara Therapeutics Inc. (BCAX) enter on August 21, 2026?

Bicara Therapeutics Inc. entered into a Sub-Sublease Agreement with Wayfair LLC to lease office space that will serve as its new corporate headquarters at 10 St. James Avenue, Boston, Massachusetts 02116.

How large is Bicara Therapeutics Inc. (BCAX)'s new headquarters space?

The new headquarters space under the Sub-Sublease Agreement covers approximately 35,090 square feet of office space at 10 St. James Avenue, Boston, Massachusetts 02116.

What is the monthly base rent under BCAX's new sub-sublease and when is it payable?

The base rent under the sub-sublease is $105,279 per month and becomes payable nine months after the defined Commencement Date of the sublease.

What security deposit did Bicara Therapeutics Inc. (BCAX) pay for the sub-sublease?

Bicara Therapeutics Inc. paid a security deposit totaling $210,540 in connection with entering into the Sub-Sublease Agreement with Wayfair LLC.

When does Bicara Therapeutics Inc. (BCAX)'s sub-sublease term start and end?

The sub-sublease term starts on the later of October 1, 2026 or the fully executed consent date, and ends on the earlier of September 30, 2028 or an earlier termination pursuant to its terms.

Who are the other parties involved in BCAX's sub-sublease consent?

The consent for the Commencement Date involves Bicara Therapeutics Inc., Wayfair LLC as sublandlord, Liberty Mutual Insurance Company as landlord, and MT Back Bay One LLC as overlandlord.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/25/2026 - 04:58 PM Accepted by SEC EDGAR 08/25/2026 - 04:58 PM Learn about SEC filing dates

FALSE000202365800020236582026-08-212026-08-21

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________

FORM 8-K

___________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): August 21, 2026

___________________________________

Bicara Therapeutics Inc.

(Exact name of registrant as specified in its charter)

___________________________________

Delaware (State or other jurisdiction of incorporation or organization)			001-42271 (Commission File Number)			85-2903745 (I.R.S. Employer Identification Number)
116 Huntington Avenue, Suite 703 Boston, MA 02116
(Address of principal executive offices and zip code)
(617) 468-4219
(Registrant's telephone number, including area code)

___________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class			Trading Symbol			Name of each exchange on which registered
Common Stock, $0.0001 par value			BCAX			The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.

Emerging growth company    ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 1.01 - Entry into a Material Definitive Agreement.

On August 21, 2026, Bicara Therapeutics Inc. (the “Company”) entered into a Sub-Sublease Agreement (the “Sublease”) with Wayfair LLC, as sublandlord (the “Sublandlord”), pursuant to which the Company, as subtenant, will lease approximately 35,090 square feet of office space for new corporate headquarters to be located at 10 St. James Avenue, Boston, Massachusetts 02116. The Sublease term commences on the later of (i) October 1, 2026 and (ii) the date of full execution of a consent between the Company, the Sublandlord, Liberty Mutual Insurance Company (as landlord) and MT Back Bay One LLC (as overlandlord) (the “Commencement Date”). The base rent under the Sublease Agreement is $105,279 per month and will become payable nine months following the Commencement Date. The Company paid a security deposit totaling $210,540 in connection with entry into the Sublease. The Sublease term ends on the earlier of (a) September 30, 2028 and (b) the date on which the Sublease is terminated pursuant to its terms. The Sublease contains customary events of default, representations, warranties and covenants.

The foregoing description of the Sublease is not complete and is qualified in its entirety by reference to the full text of the Sublease, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01 - Financial Statements and Exhibits

(d) The following exhibits are being filed herewith:

Exhibit No.						Description
10.1						Sub-Sublease Agreement, dated August 21, 2026, by and between Bicara Therapeutics Inc. and Wayfair LLC
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Bicara Therapeutics Inc.
			By:			/s/ Claire Mazumdar
			Name:			Claire Mazumdar, Ph.D., MBA
Date: August 25, 2026			Title:			Chief Executive Officer

Filing Exhibits & Attachments

4 documents

Agreements & Contracts

• EX-10.1 EX-10.1 137.9 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.7 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 22.9 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 13.3 KB